Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
TORONTO, March 01, 2016 -- Polydex Pharmaceuticals Limited (OTC Pink:POLXF) announces that, due to the continuing improvement of operations, its wholly owned subsidiary, Dextran Products Limited, has secured traditional bank financing to replace the existing private mortgage at a lower interest rate, and has also secured an additional credit line of $300,000.00
“With traditional bank support,” says George Usher, President and CEO of the company, “we now have access to additional credit for investment in new equipment and plant upgrades.”
The company has utilized private lenders in the absence of traditional bank financing for the last three years, and have had limited access to any additional credit for the last six years.
The Company’s publicly traded shares continue to be quoted on the OTC Pink platform (www.otcmarkets.com/stock/POLXF/quote)
Polydex Pharmaceuticals Limited, based in Toronto, Ontario, Canada, is engaged in the manufacture of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry, and the development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market. Company website: www.Polydex.com Twitter: @PolydexPOLXF
Note: This press release may contain forward-looking statements, within the meaning of the United States Securities Act of 1933, as amended, and the United States Securities Exchange Act of 1934, as amended, regarding Polydex Pharmaceuticals Limited, including, without limitation, statements regarding expectations about future revenues or business opportunities or potential research projects. These statements are typically identified by use of words like “may”, “could”, “might”, “expect”, “anticipate”, “believe”, or similar words. Actual events or results may differ materially from the Company’s expectations, which are subject to a number of known and unknown risks and uncertainties including but not limited to changing market conditions, future actions by the United States Food and Drug Administration or equivalent foreign regulatory authorities. Other risk factors discussed in the Company’s financial reports may also affect the actual results achieved by the Company.
Contact: Investor Relations: North Arm Capital Services, Linda Hughes, 1-877-945-1621, [email protected]
